Your wrong statement about the marketable shares position on the balance sheet of TENAX is not closed.
You fail again to deliver an explanation about the $40M which are obviously "missing" if you want to uphold your statement that marketable securities is a postion of shares to be issued in the future.
Your arguments simple do not add up, your allegations are irrational and end points just known facts.
Isn't it obvious that a R&D Biotech company which doesn't have an approved product on the market can not generate revenues through sales?! Isn't it obvious that such a company is funding its general expenses, reserach and salaries by issuing shares and debt instruments by receiving certain government grants and by managing the excess cash position to generate some revenues on the capital market?!
Again - TENX has sufficient funds to complete phase 3 study in LEVO-CTS LCOS, period. TENX does not need and will not issue new shares to fund this study, period.
Michael Jebsen, Chief Financial Officer, said: "We believe that our current capital will be sufficient to fund our levosimendan program in LCOS through a New Drug Application filing. We also remain in a strong position to proactively evaluate business development opportunities during calendar year 2015, including levosimendan’s expansion in septic shock and potential additional candidates that fit into our critical care pipeline strategy.”
TENX has fast track FDA status for LCOS
The FDA Fast Track Designation is a designation of the United States Food and Drug Administration (FDA) that facilitates the development, and expedites the review, of drugs which treat a serious or life-threatening condition and fill an unmet medical need.
The purpose of Fast Track designation is to get important new drugs to the patient earlier.
Phase 3 study LCOS has 44 patients enrolled and 41 hospitals activated and accelerating.
Phase 2/3 study for septic shock in the UK - Leopards has enrolled 250 patients and will be finished this year. www.leopards-trial.org
TENX will present in New York in April.
Only results not comments will decide about the future of this company.
